The right dose, the right escalation plan and the right diagnosis matter far more than trends
About half (54%) of those who report ever taking the drugs say it was difficult to afford them, including one in five (22%) who say it was very difficult. Having insurance coverage makes little difference to patients perceptions of the drugs affordability, with similar shares of those covered by insurance saying the drugs were difficult (53%) or very difficult (23%) to afford
Patients with type 2 diabetes require careful planning to maintain glycaemic control if GLP-1 therapy is adjusted, with typical perioperative glucose targets of 6-10 mmol/L
Mochi Health's influencer-driven campaigns resonated with younger demographics searching for affordable alternatives to brand-name Wegovy and Ozempic, which can cost upwards of $1,300/month without insurance coverage
Previous article ENSURING EXCELLENCE IN MANUFACTURING
I am still trying to understand more of the science behind it